Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc is positioned positively within the clinical-stage biopharmaceutical sector due to its innovative pipeline focused on autologous tumor infiltrating lymphocyte therapies, particularly through its CoStAR platform targeting multiple solid tumors. The company's lead candidate, ITIL-306, is strategically designed to enhance recognition of tumor-associated antigens, expanding the potential for treatment across various cancer types, including ovarian and renal cancers. Additionally, the anticipated positive updates from related industry developments may create a beneficial environment for TIL therapy advancements, potentially enhancing investor confidence and resulting in valuation upside.

Bears say

Instil Bio's recent discontinuation of AXN-2510 has eliminated a core value driver, necessitating a substantial reevaluation of the company’s overall viability and financial outlook. The company faces multiple risks, including delays in progressing candidates through clinical assessments and potential failures in delivering favorable clinical data, which may further hinder its market position. Additionally, concerns about medium- to long-term dilution risk and a perceived lack of strategic direction contribute to a negative outlook on the stock, described as "dead money" in the near term, despite a valuation gap suggesting a potential margin of safety.

Instil Bio (TIL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.